Akero Therapeutics (FRA:0K4) ROCE % : -25.66% (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Akero Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Akero Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2024 was -25.66%.

Akero Therapeutics ROCE % Historical Data

The historical data trend for Akero Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akero Therapeutics ROCE % Chart

Akero Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-45.24

-39.96

-48.91

-44.76

-32.72

Akero Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
ROCE %	Get a 7-Day Free Trial															-24.72	-25.02	-36.77	-29.06	-25.66

Akero Therapeutics ROCE % Calculation

Akero Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-136.321	/	( ( (336.602 - 18.014)	+	(532.109 - 17.54) )	/ 2 )
	=	-136.321	/	( (318.588	+	514.569)	/ 2 )
	=	-136.321	/	416.5785
	=	-32.72 %

Akero Therapeutics's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	-203.472	/	( ( (839.264 - 27.838)	+	(803.625 - 28.961) )	/ 2 )
	=	-203.472	/	( ( 811.426	+	774.664 )	/ 2 )
	=	-203.472	/	793.045
	=	-25.66 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

Akero Therapeutics (FRA:0K4) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Akero Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Akero Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Akero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (FRA:0K4) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

AKRO:USA

Address

601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080

Website

https://www.akerotx.com

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics Headlines

No Headlines